Details of the Drug Combination

General Information of Drug Combination (ID: DCCGGQR)

Drug Combination Name
Baricitinib Triamcinolone
Indication
Disease Entry Status REF
Atopic Dermatitis Phase 2 [1]
Component Drugs Baricitinib   DM4ONW5 Triamcinolone   DM98IXF
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Baricitinib
Disease Entry ICD 11 Status REF
Rheumatoid arthritis FA20 Approved [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [3]
Baricitinib Interacts with 5 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
HUMAN cyclin G-associated kinase (GAK) TT0AGBL GAK_HUMAN Inhibitor [6]
Janus kinase 2 (JAK-2) TTRMX3V JAK2_HUMAN Modulator [7]
Tyrosine-protein kinase (PTK) TTJSQEF NOUNIPROTAC Inhibitor [2]
Janus kinase 1 (JAK-1) TT6DM01 JAK1_HUMAN Modulator [7]
HUMAN adaptor-associated kinase 1 (AAK1) TTN9A16 AAK1_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------
Baricitinib Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [8]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [9]
------------------------------------------------------------------------------------
Baricitinib Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [10]
------------------------------------------------------------------------------------
Baricitinib Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cyclin-G-associated kinase (GAK) OTLM5H4P GAK_HUMAN Decreases Activity [11]
AP2-associated protein kinase 1 (AAK1) OTK9B9QT AAK1_HUMAN Decreases Activity [11]
------------------------------------------------------------------------------------
Indication(s) of Triamcinolone
Disease Entry ICD 11 Status REF
Acute adrenal insufficiency N.A. Approved [4]
Addison disease 5A74.0 Approved [4]
Allergic rhinitis CA08.0 Approved [5]
Alopecia areata ED70.2 Approved [4]
Angioedema 4A00.15 Approved [4]
Aspiration pneumonitis N.A. Approved [4]
Autoimmune haemolytic anaemia 3A20 Approved [4]
Bacterial infection 1A00-1C4Z Approved [4]
Bursitis N.A. Approved [4]
Cerebral edema 8D60.1 Approved [4]
Congenital adrenal hyperplasia 5A71.01 Approved [4]
Crohn disease DD70 Approved [4]
Cutaneous candidiasis 1F23.14 Approved [4]
Dermatitis herpetiformis EB44 Approved [4]
Diamond-Blackfan anemia N.A. Approved [4]
Disorder of orbital region N.A. Approved [4]
Epicondylitis N.A. Approved [4]
Erythema multiforme N.A. Approved [4]
Exanthem N.A. Approved [4]
Gingival disorder N.A. Approved [4]
Granuloma annulare N.A. Approved [4]
Inflammation 1A00-CA43.1 Approved [4]
Inflammatory bowel disease DD72 Approved [4]
Miliary tuberculosis N.A. Approved [4]
Multiple sclerosis 8A40 Approved [4]
Mycosis fungoides 2B01 Approved [4]
Primary cutaneous T-cell lymphoma N.A. Approved [4]
Psoriasis EA90 Approved [4]
Psoriatic arthritis FA21 Approved [4]
Rheumatic heart disease N.A. Approved [4]
Sarcoidosis 4B20.5 Approved [4]
Seasonal allergic rhinitis CA08.01 Approved [4]
Serum sickness N.A. Approved [4]
Severe asthma CA23 Approved [4]
Skin disease EA00-EM0Z Approved [4]
Subacute bursitis N.A. Approved [4]
Sympathetic ophthalmia N.A. Approved [4]
Systemic lupus erythematosus 4A40.0 Approved [4]
Acquired thrombocytopenia N.A. Investigative [4]
Asthma CA23 Investigative [4]
Beta-thalassemia major N.A. Investigative [4]
Classic Hodgkin lymphoma N.A. Investigative [4]
Follicular lymphoma 2A80 Investigative [4]
Keloid EE60 Investigative [4]
Rheumatoid arthritis FA20 Investigative [4]
Synovitis N.A. Investigative [4]
Trichinellosis N.A. Investigative [4]
Uveitis 9A96.Z Investigative [4]
Triamcinolone Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Glucocorticoid receptor (NR3C1) TTYRL6O GCR_HUMAN Modulator [13]
------------------------------------------------------------------------------------
Triamcinolone Interacts with 7 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Pro-opiomelanocortin (POMC) OTV41F7T COLI_HUMAN Decreases Response To Substance [14]
Glucocorticoid receptor (NR3C1) OTCI2YDI GCR_HUMAN Increases Activity [15]
Mineralocorticoid receptor (NR3C2) OT0F2V2Z MCR_HUMAN Decreases Activity [15]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Decreases Expression [12]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [16]
Serotransferrin (TF) OT41PEMS TRFE_HUMAN Increases ADR [17]
Insulin (INS) OTZ85PDU INS_HUMAN Increases ADR [17]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DOT(s)

References

1 ClinicalTrials.gov (NCT02576938) A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
2 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
3 ClinicalTrials.gov (NCT04345289) Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia. U.S. National Institutes of Health.
4 Triamcinolone FDA Label
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
6 Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020 Feb 15;395(10223):e30-e31.
7 Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
8 Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib. Clin Transl Sci. 2017 Nov;10(6):509-519.
9 Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran. Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01201-17.
10 FDA label of Baricitinib. The 2020 official website of the U.S. Food and Drug Administration.
11 COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020 Apr;20(4):400-402. doi: 10.1016/S1473-3099(20)30132-8. Epub 2020 Feb 27.
12 Cell-based and cytokine-directed chemical screen to identify potential anti-multiple myeloma agents. Leuk Res. 2010 Jul;34(7):917-24. doi: 10.1016/j.leukres.2009.12.002. Epub 2010 Feb 8.
13 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
14 Steroid myopathy induced by epidural triamcinolone injection. Br J Rheumatol. 1995 Apr;34(4):385-6. doi: 10.1093/rheumatology/34.4.385.
15 Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. Eur J Endocrinol. 2004 Sep;151(3):397-406. doi: 10.1530/eje.0.1510397.
16 Apoptosis of airway epithelial cells induced by corticosteroids. Am J Respir Crit Care Med. 2001 Nov 15;164(10 Pt 1):1939-47. doi: 10.1164/ajrccm.164.10.2103013.
17 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.